Abstract:Prion diseases are a group of rare, fatal neurodegenerative disorders associated with a conformational transformation of the cellular prion protein (PrP(C)) into a self-replicating and proteinase K-resistant conformer, termed scrapie PrP (PrP(Sc)). Aggregates of PrP(Sc) deposited around neurons lead to neuropathological alterations. Currently, there is no effective treatment for these fatal illnesses; thus, the development of an effective therapy is a priority. PrP peptide-based ELISA assay methods were developed for detection and immunoaffinity chromatography capture was developed for purification of naturally occurring PrP peptide autoantibodies present in human CSF, individual donor serum, and commercial preparations of pooled intravenous immunoglobulin (IVIg). The ratio of anti-PrP autoantibodies (PrP-AA) to total IgG was ∼1:1200. The binding epitope of purified PrP-AA was mapped to an N-terminal region comprising the PrP amino acid sequence KTNMK. Purified PrP-AA potently blocked fibril formation by a toxic 21-amino acid fragment of the PrP peptide containing the amino acid alanine to valine substitution corresponding to position 117 of the full-length peptide (A117V). Furthermore, PrP-AA attenuated the neurotoxicity of PrP(A117V) and wild-type peptides in rat cerebellar granule neuron (CGN) cultures. In contrast, IgG preparations depleted of PrP-AA had little effect on PrP fibril formation or PrP neurotoxicity. The specificity of PrP-AA was demonstrated by immunoprecipitating PrP protein in brain tissues of transgenic mice expressing the human PrP(A117V) epitope and Sc237 hamster. Based on these intriguing findings, it is suggested that human PrP-AA may be useful for interfering with the pathogenic effects of pathogenic prion proteins and, thereby has the potential to be an effective means for preventing or attenuating human prion disease progression.

Synthesizing and Immunization Analysis of Bovine PrPc Structural Protein Peptides

Preparations of Specific Antibodies Against PrP N-terminal or C-terminal Peptides and Preliminary Study on Establishment of ELISA Diagnostic Method

Physico-Chemical Property and Polyclonal Antibody Production of Bovine Prion Protein

Generation of Genetic Engineering Monoclonal Antibodies Against Prion Protein

Simple Method of Monoclonal Antibody Production Against Mammalian Cellular Prion Protein

Preparation of Monoclonal Antibodies Against Prion Proteins with Full-Length Hamster PrP.

[Analysis of Monoclonal Antibody Binding Sites in Ovine Prion Protein].

Prokaryotic Expression of Human Apolipoprotein E and Analyses of the Molecular Interaction Between ApoE and PrP Proteins in Vitro

Preparation and Application of Peptide Antibody Against Porcine Circovirus-like Agent P1

Generation and Identification of Phage Engineering Antibodies Library Against Hamster Prion Protein

Expression of a Chimera of Bovine Prion Protein and Yeast Ure2p Prion Domain in Escherichia Coli and Preparation of Monoclonal Antibodies Against Prion Protein

Cloning Prokaryotic Expression and Purification of Prion PrP~C51-216 from Ovis Aries

Semi-synthesis of murine prion protein by native chemical ligation and chemical activation for preparation of polypeptide-α-thioester.

Immunological Characteristics of Anti-PrP McAbs

Preparation and characterization of two monoclonal antibodies against pseudorabies virus

Capillary Isoelectric Focusing and Affinity Capillary Electrophoresis Approaches for the Determination of Binding Constants for Antibodies to the Prion Protein

Fine Mapping and Conservation Analysis of Linear B-cell Epitopes of Peste Des Petits Ruminants Virus Hemagglutinin Protein.

Human Anti-prion Antibodies Block Prion Peptide Fibril Formation and Neurotoxicity

Design Synthesis and Immunological Reaction of Epitope Peptides of ETEC K88 and K99 Fimbrial Protein

High-level Expression and Secondary Structure Analysis of the Bovine Mature Prion Protein

Expression, purification and antibody preparation using different constructs of PCV2 capsid protein.